Catumaxomab

Global CD3 Antibodies Market, Dosage, Price, & Sales Report 2023-2028: $5 Billion Opportunity, Clinical Trials Insights on 250 Antibodies, and 9 Commercially Approved CD3 Antibodies - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Uveal melanoma, Multiple myeloma, Indication, AstraZeneca, EMA, Leukemia, Catumaxomab, CD19, FDA, Acute lymphoblastic leukemia, Regeneron Pharmaceuticals, Cancer, Clinical trial, Muromonab-CD3, Antibody, CD3, Lymphoma, Amgen, Generic drug, Vaccine, Blinatumomab

The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, both these CD3 antibodies were withdrawn from the market for different clinical and commercial reasons, but, nevertheless, positioned themselves as pioneers of the CD3 antibodies market.
  • Among these is the global market value of CD3 antibodies, which has been increasing every quarter as new antibodies are approved and introduced into the market.
  • Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028 Report Highlights:
    Global CD3 Antibodies Market Opportunity: > USD 5 Billion By 2028
    CD3 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

EQS-News: LINDIS Biotech Presented Encouraging Data from Non-Muscle-Invasive Bladder Cancer Patients Treated with Trifunctional Antibody CATUMAXOMAB at EMUC22

Retrieved on: 
Sunday, November 27, 2022
CR, Recurrence, Cancer, Immune system, Congress, Macrophage, Șaeș, CRS, Risk, NMIBC, Inactivated vaccine, Urine, CIS, Carcinoma, Health, Patient, Urinary bladder, Toxicity, Cystectomy, Neoplasm, Ascites, European, Monoclonal antibody, BCG, AES, Quality of life, Bladder cancer, Data monitoring committee, Hope, B cell, Abdomen, Epithelial cell adhesion molecule, Safety, Pharmaceutical industry, Vaccine, Catumaxomab

Consistent with previous findings, CATUMAXOMAB was well tolerated, and there was no dose limiting toxicity.

Key Points: 
  • Consistent with previous findings, CATUMAXOMAB was well tolerated, and there was no dose limiting toxicity.
  • Treatment emergent adverse events (AEs) were only of grade 1-2, no serious adverse events (SAEs) were observed.
  • Our previously released compassionate use data, as well as the positive results and follow-up data from the dose escalation are strongly encouraging.
  • The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells.

Bi-Specific MAbS Global Markets Report 2022: Catumaxomab (Removab); Blinatumomab; Duligotumab; SAR 156597 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Pharmaceutical, Health, Oncology, CAGR, Cancer, COVID-19, Homeopathy, World, WHO, Method, Moab, Ascites, Conditional sentence, Inflammation, Acupuncture, Hospital, Antigen, Growth, Degenerative disease, Infection, Neurological disorder, Korea Disease Control and Prevention Agency, World Health Organization, Death, SAR, Medicine, Cell, Catumaxomab, Center, Prevalence, Vaccine, Medicinal plants, Monoclonal antibody, Ayurveda, Neutralizing antibody

The "Bi-Specific MAbS Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bi-Specific MAbS Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services.
  • Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product.
  • The main types of bi-specific are catumaxomab (removab), blinatumomab, duligotumab, SAR 156597.

DGAP-News: LINDIS Biotech Announces Online Publication of Abstract on Trifunctional Antibody CATUMAXOMAB for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022
Catumaxomab, Death, Macrophage, Company, Urine, Society, American Society of Clinical Oncology, Neoplasm, Toxicity, B cell, Abdomen, Epithelial cell adhesion molecule, Inactivated vaccine, CEO, Nature, BCG, NMIBC, Carcinoma, ASCO, Lists of World Heritage Sites, Annual general meeting, Monoclonal antibody, Patient, Cancer, Bladder cancer, Technology, HAMA, Anatomy, Ascites, Immune system, Quality of life, Urinary bladder, LLQ, Martinsried, Recurrence, Safety, Pharmaceutical industry, Medical imaging, Vaccine

Remarkably, carcinomas in situ observed at first TUR-B were no longer detectable in three of five patients following CATUMAXOMAB treatment.

Key Points: 
  • Remarkably, carcinomas in situ observed at first TUR-B were no longer detectable in three of five patients following CATUMAXOMAB treatment.
  • The strong reduction of urinary EpCAM positive cells during and after CATUMAXOMAB treatment, suggests that the trifunctional bispecific EpCAM targeting antibody binds and efficiently kills EpCAM-positive bladder cancer cells in urine milieu.
  • Due to the specific anatomy of the bladder and direct administration of the treatment via urinary catheter, CATUMAXOMAB was not detectable in the systemic circulation.
  • Bladder cancer is the 9th leading type of cancer worldwide with 430,000 new cases and about 165,000 deaths occurring every year.

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting

Retrieved on: 
Friday, May 27, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Cancer, Ascites, Immunotherapy, Lymphatic system, Isabella Tree, Annual general meeting, Bispecific monoclonal antibody, Survival, European Medicines Agency, Patient, World Health Organization, Quality of life, Society, Stomach, CD3, American Society of Clinical Oncology, CMC, Epithelial cell adhesion molecule, Efficiency, Metastasis, GC, WHO, Safety, ASCO, Pharmaceutical industry, Vaccine, Catumaxomab

About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).

Key Points: 
  • Abstract Title Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
  • Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases.
  • Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2].
  • Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).

DGAP-News: LINDIS Biotech Announces Formation of Advisory Board to Support Next Phase of Growth

Retrieved on: 
Tuesday, December 21, 2021
Doctor of Philosophy, Regulatory affairs, Advisory board, List of life sciences, Principal, German Association for Housing, Urban and Spatial Development, University, Martinsried, DIA, Transplant, Organ (anatomy), Lists of World Heritage Sites, Technology, CEO, Abdomen, Monoclonal antibody, Consultant, Bayer, Carcinoma, Epithelial cell adhesion molecule, Pharmacy, Safety, Neoplasm, Industry, Association, Company, Clinic, DGRA, Catumaxomab, Ernst, Macrophage, Immune system, Ernst & Young, B cell, Cancer, The Advisory Board Company, Vaccine, Ascites, CATUMAXOMAB, LINDIS Biotech GmbH, CATUMAXOMAB, LINDIS BIOTECH GMBH

"The formation of our Advisory Board with leading experts in their respective field is an important step to further drive the company's development with compelling long-term as well as near-term inflection points ahead," said Dr. Horst Lindhofer, founder and CEO of LINDIS Biotech.

Key Points: 
  • "The formation of our Advisory Board with leading experts in their respective field is an important step to further drive the company's development with compelling long-term as well as near-term inflection points ahead," said Dr. Horst Lindhofer, founder and CEO of LINDIS Biotech.
  • "The diverse areas of expertise and insight of the Advisory Board will be essential in the execution of our strategy.
  • It will help us accelerate the development of our drug candidates, steer future applications and forge new commercial partnerships.
  • Inaugural members of the LINDIS Biotech Advisory Board include:
    Dr. Franzpeter Bracht (PhD) - Dr. Bracht is an expert in business development & establishing new life sciences companies with over 25 years of experience in senior level positions.

LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Retrieved on: 
Wednesday, December 1, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, World Health Organization, NMIBC, Safety, CEO, Epithelial cell adhesion molecule, European Medicines Agency, CMC, Neurogenic bladder dysfunction, WHO, Recurrence, Cancer, Catumaxomab, Lymphatic system, DABT, Ascites, Neoplasm, Bladder cancer, CD3, Bispecific monoclonal antibody, BCG, Efficiency, Vaccine, Pharmaceutical industry, Catumaxomab, LintonPharm, CATUMAXOMAB, LINTONPHARM

A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC.

Key Points: 
  • A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC.
  • Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3].
  • The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer.
  • First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity.

Bi-Specific MAbS Global Market Report 2021-2030: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Biotechnology, Pharmaceutical, Health, Medical specialties, Immunology, Clinical medicine, Medicine, Bispecific monoclonal antibody, Monoclonal antibody, Catumaxomab, Blinatumomab, Mab, Antibody

The "Bi-Specific MAbS Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bi-Specific MAbS Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report focuses on bi-specific mabs market which is experiencing strong growth.
  • The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services.
  • The bi-specific MAbs market covered in this report is segmented by type into catumaxomab (removab); blinatumomab; duligotumab; SAR 156597.

DGAP-News: LINDIS Biotech Announces Publication of Patient Data Highlighting the Potential of Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer in Peer-Reviewed Journal

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Catumaxomab, Epithelial cell adhesion molecule, Monoclonal antibodies, Cancer immunotherapy, Bladder cancer, Urinary bladder, Trifunctional antibody, Bispecific monoclonal antibody, NMIBC, CATUMAXOMAB, LINDIS Biotech GmbH, NMIBC, CATUMAXOMAB, LINDIS BIOTECH GMBH

Researchers evaluated the potential of intravesically administered (administration via a catheter directly into the bladder) CATUMAXOMAB, a trifunctional bispecific epithelial cell adhesion molecule (EpCAM) targeting antibody, as a potential first in class immuno-oncology treatment option for non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • Researchers evaluated the potential of intravesically administered (administration via a catheter directly into the bladder) CATUMAXOMAB, a trifunctional bispecific epithelial cell adhesion molecule (EpCAM) targeting antibody, as a potential first in class immuno-oncology treatment option for non-muscle invasive bladder cancer (NMIBC).
  • Data from two patients with recurrent NMIBC, treated with intravesically administered CATUMAXOMAB on a named-patient basis, suggest that the trifunctional bispecific EpCAM targeting antibody highly efficiently binds and kills EpCAM-positive bladder cancer cells in urine milieu.
  • Following the treatment, no tumors were detected in the bladder and no tumor cells were observed in the patients' urine samples.
  • In 2017, LintonPharm, partner of LINDIS Biotech, in-licensed four Triomab(R) antibodies from LINDIS Biotech for further development and commercialization in the Asia-Pacific region.

LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, April 13, 2021
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Infectious causes of cancer, Bladder cancer, Aging-associated diseases, Cancer, Urinary bladder, Clinical medicine, Health, BCG vaccine, Catumaxomab, LintonPharm

\xe2\x80\x9cPatients with NMIBC BCG failure have high rates of tumor recurrence and often face a lifetime of surgical intervention which may impact bladder function.

Key Points: 
  • \xe2\x80\x9cPatients with NMIBC BCG failure have high rates of tumor recurrence and often face a lifetime of surgical intervention which may impact bladder function.
  • New treatment options are needed and we are hopeful that this study puts us one step closer toward helping these patients.\xe2\x80\x9d\nBladder cancer is the 10th most common cancer worldwide.
  • In 2020, bladder cancer was diagnosed in approximately 573,278 patients globally and approximately 1.8 million people were living with this form of cancer over a five-year period [1].
  • NMIBC is a cancer found in the tissue that lines the inner surface of the bladder and accounts for approximately 75 percent of all bladder cancer [2].